Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976648 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
A Phase 2 study, sponsored by Lakefront Biotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03976648: Clinical Trial Phase 2 study, sponsored by Lakefront Biotherapeutics.
NCT03976648 is a Phase 2 study that was terminated before completion, run by Lakefront Biotherapeutics. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03976648, a Phase 2 study, was terminated before completion, sponsored by Lakefront Biotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study was the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study was to see how GLPG1690 was tolerated in participants with systemic sclerosis and whether there were any side effects in a long-term treatment period.
Interventions
- DRUG GLPG1690
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2021-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03976648
The ClinicalTrials.gov registry entry for NCT03976648 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GLPG1690 is the first listed.
NCT03976648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03976648 about?
NCT03976648 is a clinical study titled "A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis". This study was the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study was to see how GLPG1690 was tolerated in participants with systemic sclerosis and whether there were any side effects in a long-term treatment period.
What is the current status of trial NCT03976648?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-07-18. Estimated completion is 2021-04-13.
What interventions are being tested in trial NCT03976648?
The interventions under investigation include: GLPG1690 (DRUG).
Who is sponsoring clinical trial NCT03976648?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.